Abstract:Importance: Increasing levels of high-density lipoprotein (HDL) cholesterol through pharmacologic inhibition of cholesteryl ester transfer protein (CETP) is a potentially important strategy for prevention and treatment of cardiovascular disease (CVD).Objective: To use genetic variants in the CETP gene to assess potential risks and benefits of lifelong lower CETP activity on CVD and other outcomes.Design, Setting, and Participants: This prospective biobank study included 151 217 individuals aged 30 to 79 years who were enrolled from 5 urban and 5 rural areas of China from June 25, 2004, through July 15, 2008. All participants had baseline genotype data, 17 854 of whom had lipid measurements and 4657 of whom had lipoprotein particle measurements. Median follow-up of 9.2 years (interquartile range, 8.2-10.1 years) was completed January 1, 2016, through linkage to health insurance records and death and disease registries.Exposures: Five CETP variants, including an East Asian loss-of-function variant (rs2303790), combined in a genetic score weighted to associations with HDL cholesterol levels.Main Outcomes and Measures: Baseline levels of lipids and lipoprotein particles, cardiovascular risk factors, incidence of carotid plaque and predefined major vascular and nonvascular diseases, and a phenome-wide range of diseases.Results: Among the 151 217 individuals included in this study (58.4% women and 41.6% men), the mean (SD) age was 52.3 (10.9) years. Overall, the mean (SD) low-density lipoprotein (LDL) cholesterol level was 91 (27) mg/dL; HDL cholesterol level, 48 (12) mg/dL. CETP variants were strongly associated with higher concentrations of HDL cholesterol (eg, 6.1 [SE, 0.4] mg/dL per rs2303790-G allele; P = 9.4 × 10-47) but were not associated with lower LDL cholesterol levels. Within HDL particles, cholesterol esters were increased and triglycerides reduced, whereas within very low-density lipoprotein particles, cholesterol esters were reduced and triglycerides increased. When scaled to 10-mg/dL higher levels of HDL cholesterol, the CETP genetic score was not associated with occlusive CVD (18 550 events; odds ratio [OR], 0.98; 95% CI, 0.91-1.06), major coronary events (5767 events; OR, 1.08; 95% CI, 0.95-1.22), myocardial infarction (3118 events; OR, 1.14; 95% CI, 0.97-1.35), ischemic stroke (13 759 events; OR, 0.94; 95% CI, 0.86-1.02), intracerebral hemorrhage (6532 events; OR, 0.94; 95% CI, 0.83-1.06), or other vascular diseases or carotid plaque. Similarly, rs2303790 was not associated with any vascular diseases or plaque. No associations with nonvascular diseases were found other than an increased risk for eye diseases with rs2303790 (4090 events; OR, 1.43; 95% CI, 1.13-1.80; P = .003).Conclusions and Relevance: CETP variants were associated with altered HDL metabolism but did not lower LDL cholesterol levels and had no significant association with risk for CVD. These results suggest that in the absence of reduced LDL cholesterol levels, increasing HDL cholesterol levels by inhibition of CETP may not confer significant benefits for CVD.

Association of cholesteryl ester transfer protein activity and TaqIB polymorphism with lipoprotein variations in Japanese subjects

4P-1030 Diplotype analysis identified lower expression haplotype of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism

Association Between Cholesteryl Ester Transfer Protein Gene Polymorphisms and Variations in Lipid Levels in Patients with Coronary Heart Disease.

Association Between Cholesteryl Ester Transfer Protein-Taqib Polymorphism and Coronary Heart Disease

Cholesteryl ester transfer protein gene effect on CETP activity and plasma high‐density lipoprotein in European populations

The association of the cholesterol ester transfer protein TaqIB polymorphism with the plasma lipids in patients with acute coronary syndrome

Association Of Two Cetp Polymorphisms With Hdl Levels In The Chinese Obese Population

Relationship Between the Cholesterol Ester Transfer Protein TaqIB Polymorphism and the Lipid-Lowering Effect of Atorvastatin in Patients with Coronary Atherosclerotic Heart Disease.

TaqIB Polymorphism in the CETP Gene Modulates the Impact of HC/LF Diet on the HDL Profile in Healthy Chinese Young Adults

Association of Cholesteryl Ester Transfer Protein (CETP) Gene Polymorphism, High Density Lipoprotein Cholesterol and Risk of Coronary Artery Disease: a Meta-Analysis Using a Mendelian Randomization Approach

[Effects of Cholesterol Ester Transfer Protein Taq1B Polymorphism on Response of Serum HDL-C to Dietary Factors in Hyperlipidemia Patients].

[Influence of CETP gene -629C/A polymorphism on the efficacy of atorvastatin treatment and clinical outcome].

Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin

Association of Gene Polymorphism at Cholesterol Ester Transfer Protein Locus with Obesity and Response to Dietary Intervention in Obesity

Cholesteryl Ester Transfer Protein Concentrations in Subjects with Various Dyslipidaemias

ASSA13-16-1 the Influence of CETP –629C/A Polymorphism on Atorvastatin Treatment Efficacy and Clinical Outcome in Patients with Coronary Artery Disease

Identification of Genetic Markers Associated With High-Density Lipoprotein-Cholesterol by Genome-Wide Screening in a Japanese Population The Suita Study

Diff Erential Eff Ect of ATP Binding Cassette Transporter A1 R219K and Cholesteryl Ester Transfer Protein TaqIB Genotypes on HDL-C Levels in Overweight/obese and Non-Obese Chinese Subjects

CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population

[Effects of Genetic Variations of Cholesteryl Ester Transfer Protein on Atorvastatin Treatment Efficacy and Clinical Outcomes in Patients with Coronary Artery Disease].

Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults